全部商品分类首页
XL388
.jpg)
1/2
用小程序，查商品更便捷
产品介绍
产品介绍
产品信息
抗原名称
mTORC1 ,mTOR,mTORC2
商品描述
XL388是一种高效的，ATP竞争性的mTOR选择性抑制剂，IC50为9.9 nM，比作用于紧密相关的PI3K激酶选择性高1000倍。在MCF-7细胞中，XL388抑制了mTORC1磷酸化p70S6K（T389），IC50是94 nM。XL388抑制mTORC2的磷酸化AKT（S473），IC50是350 nM。在体外，XL388抑制实体和造血肿瘤细胞系的活性以及MCF-7细胞系增殖（IC50为1.37 μM）。
分子量
455.5
纯度
>98%
可溶性
DMSO ：22 mg/mL (48.3 mM)
In vitro(体外研究)
In MCF-7 cells, XL388 blocks mTORC1 phosphorylation of p70S6K (T389)with an IC50 value of 94 nM and blocks mTORC2 phosphorylationof AKT (S473) with an IC50 value of 350 nM. In vitro, XL388 inhibits the viability of solid and hematopoietic tumor cell lines. The proliferation IC50 is 1.37 μM in MCF-7 cell line. XL388 also synergizes with chemotherapeutics in cell-based assays to block cell viability.
In vivo(体内研究)
When dosed orally once daily in mice, XL388 shows robust anti-tumor activity in multiple xenograft models including > 100% tumor growth inhibition in the MCF-7 xenograft model. XL388 displays good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. The mean plasma protein binding of XL388 in human, monkey, dog, rat, and mouse plasma is evaluated at 5 μM and is determined to be 86%, 90%, 89%, 85%, and 84%, respectively. Oral administration of XL388 to athymic nude mice implanted with human tumor xenografts afforded significant and dose-dependent antitumor activity. Strong inhibition of both mTORC1 and mTORC2 is achieved 4−8 h following administration orally at 100 mg/kg. Modest inhibition (39−45%) of phosphorylation of the PI3K target AKT (T308) is also observed 4−8 h post dose.
背景
分子式
C23H22FN3O4S
CAS号
1251156-08-7
制备和贮存
保存方式
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
声明 ：本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。